Comparison Overview

AbbVie

VS

Intas Pharmaceuticals

AbbVie

1 Waukegan Road, None, North Chicago, Illinois, US, 60064
Last Update: 2025-12-11
Between 800 and 849

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 58,020
Subsidiaries: 15
12-month incidents
0
Known data breaches
1
Attack type number
1

Intas Pharmaceuticals

Sarkhej Gandhinagar Highway, Near Sola Bridge, Ahmedabad, Gujarat, IN
Last Update: 2025-12-11
Between 750 and 799

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 18,700
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/abbvie.jpeg
AbbVie
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/intas-pharmaceuticals.jpeg
Intas Pharmaceuticals
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
AbbVie
100%
Compliance Rate
0/4 Standards Verified
Intas Pharmaceuticals
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AbbVie in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Intas Pharmaceuticals in 2025.

Incident History — AbbVie (X = Date, Y = Severity)

AbbVie cyber incidents detection timeline including parent company and subsidiaries

Incident History — Intas Pharmaceuticals (X = Date, Y = Severity)

Intas Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/abbvie.jpeg
AbbVie
Incidents

Date Detected: 6/2023
Type:Breach
Attack Vector: Exploitation of Vulnerability
Motivation: Financial gain
Blog: Blog
https://images.rankiteo.com/companyimages/intas-pharmaceuticals.jpeg
Intas Pharmaceuticals
Incidents

No Incident

FAQ

AbbVie company demonstrates a stronger AI Cybersecurity Score compared to Intas Pharmaceuticals company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

AbbVie company has historically faced a number of disclosed cyber incidents, whereas Intas Pharmaceuticals company has not reported any.

In the current year, Intas Pharmaceuticals company and AbbVie company have not reported any cyber incidents.

Neither Intas Pharmaceuticals company nor AbbVie company has reported experiencing a ransomware attack publicly.

AbbVie company has disclosed at least one data breach, while the other Intas Pharmaceuticals company has not reported such incidents publicly.

Neither Intas Pharmaceuticals company nor AbbVie company has reported experiencing targeted cyberattacks publicly.

Neither AbbVie company nor Intas Pharmaceuticals company has reported experiencing or disclosing vulnerabilities publicly.

Neither AbbVie nor Intas Pharmaceuticals holds any compliance certifications.

Neither company holds any compliance certifications.

AbbVie company has more subsidiaries worldwide compared to Intas Pharmaceuticals company.

AbbVie company employs more people globally than Intas Pharmaceuticals company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither AbbVie nor Intas Pharmaceuticals holds SOC 2 Type 1 certification.

Neither AbbVie nor Intas Pharmaceuticals holds SOC 2 Type 2 certification.

Neither AbbVie nor Intas Pharmaceuticals holds ISO 27001 certification.

Neither AbbVie nor Intas Pharmaceuticals holds PCI DSS certification.

Neither AbbVie nor Intas Pharmaceuticals holds HIPAA certification.

Neither AbbVie nor Intas Pharmaceuticals holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A weakness has been identified in itsourcecode Online Pet Shop Management System 1.0. This vulnerability affects unknown code of the file /pet1/addcnp.php. This manipulation of the argument cnpname causes sql injection. The attack can be initiated remotely. The exploit has been made available to the public and could be exploited.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A security flaw has been discovered in Tenda AX9 22.03.01.46. This affects the function image_check of the component httpd. The manipulation results in use of weak hash. It is possible to launch the attack remotely. A high complexity level is associated with this attack. It is indicated that the exploitability is difficult. The exploit has been released to the public and may be exploited.

Risk Information
cvss2
Base: 2.6
Severity: HIGH
AV:N/AC:H/Au:N/C:N/I:P/A:N
cvss3
Base: 3.7
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A weakness has been identified in code-projects Student File Management System 1.0. This issue affects some unknown processing of the file /admin/update_student.php. This manipulation of the argument stud_id causes sql injection. The attack is possible to be carried out remotely. The exploit has been made available to the public and could be exploited.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A security flaw has been discovered in code-projects Student File Management System 1.0. This vulnerability affects unknown code of the file /admin/save_user.php. The manipulation of the argument firstname results in sql injection. The attack can be executed remotely. The exploit has been released to the public and may be exploited.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was identified in code-projects Student File Management System 1.0. This affects an unknown part of the file /admin/update_user.php. The manipulation of the argument user_id leads to sql injection. Remote exploitation of the attack is possible. The exploit is publicly available and might be used.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X